The medtech space continues to advance at an exhilarating pace, with more health developments emerging each year. Biobanks, a large collection of vital samples that are kept primarily for use in health and medical research, have taken off in recent years. According to Transparent Market Research, the global biobanking market was valued at $50.1 billion in 2021 and is expected to grow to more than $87.4 billion by the end of 2031.
North America captured the largest share of the global biobanking market in 2021. Increased adoption of advanced technologies and increased awareness of biobanking have allowed the region to thrive and offer more opportunities to benefit human health.
Recently, I sat with Salvatore Viscomichief medical officer of GoodCellOne of the world’s premier biobanking institutions. It provides insight into what to expect in the future of biobanking and how GoodCell is paving the way for more innovations that can help save lives from previously incurable conditions.
Salvatore and Godsel will be in BIOMED device in Boston From September 28-29 In the Boston Convention and Exhibition Center. BIOMEDevice Boston brings together top engineers, business leaders, disruptive companies, and innovative thinkers from the top Northeast startups and medical device manufacturers to inspire the next life-changing medical device. Register here to attend the show.
Adrienne: For those of you who don’t know who you are, tell us a little bit about yourself and how you fit into the biomedical industry.
Salvatore: I am a practicing physician, researcher, and entrepreneur. I am currently leading GoodCell’s line of genetic and biomarker testing, developing a healthcare platform that harnesses the power of blood to inform and restore health. Previously, I spent 14 years as a faculty member at Harvard Medical School, and concurrently as a physician at Brigham and Women’s Hospital. In this capacity, she has held various administrative and clinical positions, including director of admissions for the Harvard Residency Program. As a medical imaging expert, I have published and presented nationally and internationally. She co-founded Brigham NightWatch, the world’s first academic network for teleradiology. In addition, she served as an executive and board member at FreMon Scientific where she led the development of a next-generation blood product management solution that was FDA-approved and eventually brought to market. My path to medicine began when I was at Columbia University, earned a bachelor’s degree in neuropsychology, and completed my residency and residency at Harvard Medical School. I also serve on the board of the Make-A-Wish Foundation in Massachusetts/Rhode Island. In 2016, she completed the Executive Education Program at Harvard Business School.
A: We are very excited to have your support as a featured speaker at BIOMEDevice Boston. Do you have any exciting news you’d like to share from GoodCell?
S: GoodCell, a life sciences company, is a preventative healthcare service launched earlier this year that allows people to prepare for personalized medicine opportunities by stocking their biomaterials through Personal Biobanking for potential future cell therapies.
This is an exciting time to have healthy cell storage at your fingertips given the thousands of cell and genetic therapies being studied to treat diseases and conditions that may affect millions of Americans. This ranges from neurodegenerative diseases such as Parkinson’s disease to some types of cancer to major chronic conditions such as heart disease and diabetes. Based on the current clinical trial pipeline, the FDA expects to approve 10-20 new cell and gene therapies annually starting in 2025.
Furthermore, GoodCell is developing a new genetic test that evaluates dynamic genetic changes in our cells, rather than just the risks inherited from traditional genetic tests. Measuring specific physical changes in the blood over time can be used to predict the risk of cardiovascular disease and some types of cancer as well as to find out why some people develop abnormal inflammatory responses when infected with COVID-19.
A: What trends do you see coming down the pipeline and how will they be highlighted at this event?
S: I see trends toward patient democratization in the form of personalized dashboards that integrate health information. Patients will also be empowered with advanced home health monitoring to replace traditional hospital care and clinical trials, which will lead to more effective screening and disease monitoring. Finally, I believe that the integration of data from multiple sources will allow the creation of binary numerical models to predict specific health risks and inform the development of treatments.
A: What are you most looking forward to at BIOMEDevice Boston this month?
S: I look forward to seeing new hardware and software solutions that treat chronic diseases that have been very difficult to manage effectively in the past. Specifically, innovative tools that capture physiological and biological data to enable better remote patient monitoring, whether for in-home hospital care or for decentralized clinical trials.